Cases & Deals

  • Home
  • Practices
  • Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petition

Share

Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petition

November 2015

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in successfully defending an IPR petition filed by Coalition for Affordable Drugs VI LLC (CFAD) - a company formed by hedge fund manager Kyle Bass - against U.S. Patent No. 5,635,517, which is listed in the Orange Book for Celgene's REVLIMID® brand drug. Following Celgene's filing of its Patent Owner Preliminary Response, the PTAB denied CFAD's petition in its entirety, finding that CFAD had failed to establish a reasonable likelihood that it would prevail in showing the unpatentability of any claim of the '517 patent.

Coalition for Affordable Drugs VI LLC et al. v. Celgene Corporation, IPR2015-01169 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.